Reset Mind Sciences, established in 2021, is a subsidiary of Little Green Pharma, a company known for its work in medicinal cannabis. Reset Mind Sciences is focused on producing and administering the psychedelic medication psilocybin derived from its in-house cultivated mushrooms1.
The company is conducting Western Australia’s first psilocybin-based clinical trial to develop best practice protocols for patient administration of psychedelics. In the emerging field of psychedelic medicine in Australia, Reset Mind Sciences is positioned as a first mover, leveraging the experience and infrastructure of Little Green Pharma2.
Reset Mind Sciences sees potential in using psychedelic medicines, particularly psilocybin, for treating mental health conditions. The company’s treatment approach is based on the concept of a ‘reset of the brain,’ disrupting pre-existing brain communication to provide lasting patient potential benefits.
The team includes CEO Shaun Duffy, Executive Director Angus Caithness, and Independent Non-Executive Director and Chairperson Hon. Cheryl Edwardes AM. Their Clinical Advisory Board comprises experts in psychedelic-assisted psychotherapy, including Dr. Stephen Bright, Ms. Renee Harvey, and Ms. Eternity Hausen.
Activities
B2B
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates